Bone Lump (Bone Tumour)

DEFINITION & OVERVIEW

Definition: A bone lump is an osseous or subperiosteal mass arising from the cortex, medulla, or surface of a bone, which may represent benign neoplasms, primary bone sarcomas, metastatic disease, infection (osteomyelitis), or non-neoplastic reactive processes.
Epidemiology & Demographics:
- In patients age > 40 years, bone lesions are overwhelmingly Metastatic Carcinoma or Multiple Myeloma.
- In children and young adults (age < 30 years), benign bone lesions (e.g., osteochondroma, non-ossifying fibroma) predominate, but primary bone sarcomas (Osteosarcoma, Ewing Sarcoma) must be excluded.
Anatomical Subregions: Epiphyseal (e.g., Giant Cell Tumor, Chondroblastoma), Metaphyseal (e.g., Osteosarcoma, Osteochondroma), or Diaphyseal (e.g., Ewing Sarcoma, Osteoid Osteoma, Fibrous Dysplasia).

In any patient aged > 40 years presenting with a new, destructive, or painful bone lesion, think “BLT with a Kosher Pickle” for the common osteolytic/osteoblastic metastases: Breast, Lung, Thyroid, Kidney, and Prostate (plus Multiple Myeloma).

APPROACH

Step 1: Clinical Red Flag Screening
- Pain Pattern: Constant, progressive, deep, aching bone pain, especially night pain waking the patient from sleep or unprovoked resting pain (malignancy red flag).
- Systemic Features: Unexplained weight loss, night sweats, fevers, malaise, hypercalcaemia.
- Mass Characteristics: Rapidly enlarging lesion, hard fixed mass > 5 cm, warm/erythematous skin over bone, or associated soft tissue mass extension.
- Structural Instability: Impending Pathological Fracture (Mirels’ score >= 9 -> urgent prophylactic orthopedic stabilization).
Step 2: Plain Radiograph Assessment (The “Lodwick” Criteria)
- Obtain orthogonal views (AP and Lateral) of the entire affected bone.
- Assess Radiographic Aggressiveness:
  - Benign / Non-Aggressive: Well-defined margin, narrow zone of transition, sclerotic border, intact cortex, no periosteal reaction, no soft-tissue mass.
  - Malignant / Aggressive: Ill-defined / permeative / “moth-eaten” margin, wide zone of transition, cortical destruction, aggressive periosteal reaction (Codman’s triangle, “sunburst”, or “onion-skin” multilamellated pattern), soft tissue mass.
Step 3: Diagnostic Branching Logic
- Aggressive Radiographic Features / Red Flags Present: -> Do NOT Biopsy in Primary Care. Obtain urgent staging MRI and refer directly to a specialized Sarcoma / Orthopaedic Oncology Multidisciplinary Team (MDT).
- Classic Incidental Benign Lesion (e.g., Non-Ossifying Fibroma, Osteochondroma): -> Conservative follow-up or reassurance.
- Lytic Bone Lesion in Age > 40: -> Staging CT chest/abdomen/pelvis + Myeloma screen (Serum Free Light Chains, SPEP/UPEP) + Bone Scan.

Never perform an unplanned excisional biopsy or puncture of a suspected primary bone tumor outside of a specialist sarcoma center. A poorly placed biopsy tract can contaminate tissue planes, necessitating limb amputation rather than limb-sparing surgery.

DIFFERENTIAL DIAGNOSIS

Malignant Bone Lesions:
- Osteosarcoma (Most Common Primary Bone Malignancy in Youth):
  - Distinguishing features: Bimodal age peak (10–25 years and > 60 years); metaphyseal (distal femur > proximal tibia > proximal humerus); mixed blastic/lytic lesion, Codman’s triangle, and “sunburst” spiculation of periosteal bone formation.
- Ewing Sarcoma:
  - Distinguishing features: Children/adolescents (age 5–20); diaphyseal/metadiaphyseal region of long bones and pelvis; permeative bone destruction, “onion-skin” lamellated periosteal reaction, large soft tissue component; fever/leukocytosis mimicking osteomyelitis ($t(11;22)$ translocation).
- Chondrosarcoma:
  - Distinguishing features: Adults age 40–70; axial skeleton/pelvis/proximal femur; lobulated matrix with “rings and arcs” / “popcorn” calcifications on plain radiograph; resistant to radiotherapy/chemotherapy.
- Multiple Myeloma / Bone Metastases:
  - Distinguishing features: Age > 50; multiple discrete “punched-out” lytic lesions without sclerotic rims on skull/spine X-rays; elevated serum protein, Bence-Jones proteinuria, hypercalcaemia, and renal impairment (CRAB criteria).

Benign Bone Tumors & Pseudotumors:
- Osteochondroma (Exostosis – Most Common Benign Tumor):
  - Distinguishing features: Bony outgrowth on bone surface pointing away from adjacent joint, with continuous marrow and cortex cavity; cartilage cap < 1.5–2 cm (cartilage cap > 2 cm indicates malignant transformation to secondary chondrosarcoma).
- Osteoid Osteoma:
  - Distinguishing features: Adolescents/young adults; diaphyseal cortex; severe nocturnal bone pain dramatically relieved by NSAIDs/Aspirin; radiograph shows a small radiolucent nidus (< 1.5 cm) surrounded by dense reactive cortical sclerosis.
- Giant Cell Tumor of Bone (GCTB):
  - Distinguishing features: Young adults age 20–40 (skeletally mature with closed epiphyses); strictly epiphyseal extending to subarticular surface (around the knee); purely lytic, eccentric, expansile “soap-bubble” appearance without peripheral sclerosis.
- Non-Ossifying Fibroma (NOF) / Fibrous Cortical Defect:
  - Distinguishing features: Incidental finding in pediatric/adolescent patients; eccentric, bubbly lytic lesion with well-defined scalloped sclerotic margins in the metaphysis; spontaneously ossifies and disappears with age.
- Osteomyelitis / Brodie’s Abscess:
  - Distinguishing features: Subacute lucent lesion with surrounding dense sclerosis; pain, localized warmth, elevated inflammatory markers (CRP, ESR).

The classic hallmark of an Osteoid Osteoma is severe, localized bone pain that worsens at night and is dramatically and rapidly relieved by low-dose Aspirin or NSAIDs (due to high prostaglandin production by the vascular nidus).

INVESTIGATIONS

First-Line / Mandatory Baseline Imaging & Labs:
- Orthogonal Plain Radiographs (AP & Lateral): Mandatory first test. Evaluates lesion location, margins, cortical breach, matrix type (osteoid vs chondroid), and periosteal reaction.
- Baseline Blood Panel: Full Blood Count (cytopenias, infection), ESR & CRP, Serum Corrected Calcium, Phosphate, Alkaline Phosphatase (ALP – elevated in osteosarcoma and Paget’s disease), Serum Creatinine.
- Myeloma Screen (If age > 40): Serum Protein Electrophoresis (SPEP), Urine Protein Electrophoresis (UPEP), Serum Free Light Chains (sFLC).
Targeted / Specialized Diagnostic & Staging Workup:
- MRI of the Entire Affected Bone (with IV Gadolinium): Gold standard to delineate intraosseous tumor extent, marrow replacement, joint space involvement, skip lesions, and neurovascular proximity.
- Staging CT Chest / Abdomen / Pelvis: Detects pulmonary metastases (lungs are the most common site of metastasis for primary bone sarcomas) and identifies occult primary carcinoma in metastatic disease.
- Technetium-99m Whole-Body Bone Scintigraphy / 18F-FDG PET-CT: Assesses multifocal skeletal lesions, metabolic activity, and occult distant metastases.
- Image-Guided Core Needle Biopsy (Specialist Center Only): Mandatory for definitive histopathological diagnosis prior to neoadjuvant therapy or operative intervention.

Radiograph showing an aggressive osteosarcoma involving the distal femur. — Radiograph showing osteosarcoma of the distal femur. Credit: Scott Dulebohn, MD and S. Bhimji, MD, via Wikimedia Commons, CC BY 4.0.

Radiograph showing a bony exostosis arising from the proximal tibia. — Radiograph showing an osteochondroma arising from the proximal tibia. Credit: Hellerhoff, via Wikimedia Commons, CC BY-SA 3.0.

The skull X-ray in Multiple Myeloma demonstrates classic “punched-out” lytic lesions that lack reactive sclerotic borders because myeloma cells release DKK-1 and other cytokines that completely suppress osteoblast bone repair.

Lateral skull radiograph containing numerous discrete punched-out osteolytic lesions. — Skull radiograph showing multiple punched-out osteolytic lesions, a classic but not pathognomonic appearance of multiple myeloma. Credit: Medicalpal, via Wikimedia Commons, CC BY-SA 4.0.

CRITICAL MANAGEMENT

Primary Bone Sarcoma Pathway (Osteosarcoma, Ewing Sarcoma):
- Immediate MDT Referral: Refer to a dedicated tertiary orthopedic oncology and sarcoma center before any surgical intervention.
- Neoadjuvant Chemotherapy: Multimodal systemic chemotherapy (e.g., MAP: Methotrexate, Doxorubicin [Adriamycin], Cisplatin) prior to definitive surgery to shrink tumor and treat micrometastatic disease.
- Limb-Salving Resection & Reconstruction: Wide local surgical excision with clear oncological margins + modular endoprosthetic replacement or biological reconstruction.
Pathological Fracture Risk Assessment & Management (Mirels’ Score):
- Mirels’ Criteria (Score 1–3 for each: Site, Pain, Lesion Type, Size):
  - Score >= 9: High fracture risk (> 33%) -> Prophylactic Orthopedic Internal Fixation (Intramedullary nailing / cemented arthroplasty) prior to radiation therapy or mobilization.
  - Score <= 7: Low risk (< 5%) -> Conservative management / radiation therapy.
Osteoid Osteoma Definitive Treatment:
- First-Line Medical Therapy: Daily NSAIDs (if pain is controlled and patient tolerates).
- Minimally Invasive Interventional Procedure: CT-guided Percutaneous Radiofrequency Ablation (RFA) of the nidus (cure rate > 90%).

Always calculate Mirels’ Score for metastatic or lytic long-bone lesions. A score of 9 or greater is a surgical emergency requiring immediate prophylactic internal fixation before a catastrophic pathological fracture occurs.

REFERENCES

Gerrand C, Amary F, Anwar HA, et al. UK guidelines for the management of bone sarcomas. Br J Cancer. 2025;132(1):32–48. doi:10.1038/s41416-024-02868-4
Ahlawat S, Lenchik L, Baker JC, et al. ACR Appropriateness Criteria® Suspected Primary Bone Tumors: 2024 Update. J Am Coll Radiol. 2025;22(5 Suppl):S440–S454. doi:10.1016/j.jacr.2025.02.020
National Institute for Health and Care Excellence. Suspected cancer: recognition and referral [Internet]. London: NICE; 2015 [updated 2026; cited 2026 Aug 31]. Available from: https://www.nice.org.uk/guidance/ng12
National Cancer Institute. Osteosarcoma and undifferentiated pleomorphic sarcoma of bone treatment (PDQ®)–health professional version [Internet]. Bethesda (MD): National Cancer Institute; [updated 2024 Dec 2; cited 2026 Aug 31]. Available from: https://www.cancer.gov/types/bone/hp/osteosarcoma-treatment-pdq
National Cancer Institute. Ewing sarcoma treatment (PDQ®)–health professional version [Internet]. Bethesda (MD): National Cancer Institute; [updated 2024 Nov 27; cited 2026 Aug 31]. Available from: https://www.cancer.gov/types/bone/hp/ewing-treatment-pdq
Mirels H. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989;(249):256–264. PMID:2684463.
Tepelenis K, Skandalakis GP, Papathanakos G, et al. Osteoid osteoma: an updated review of epidemiology, pathogenesis, clinical presentation, radiological features, and treatment option. In Vivo. 2021;35(4):1929–1938. doi:10.21873/invivo.12459